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technology to exchange crucial information.1 
The scope of telemedicine in Poland is regulated 
by law,2,3 with selected services found on the list 
of state ‑reimbursed telemedicine procedures. This 
Introduction Telemedicine involves diagnostic, 
therapeutic, prophylaxis ‑oriented, didactic, and 
educational services offered remotely by health‑


















Telemedicine involves diagnostic, therapeutic and educational services being offered remotely by healthcare 
professionals to exchange crucial clinical information. It is a rapidly developing form of medical activity 
and part of medical industry, with advanced technologies already available in Poland. Cardiology is one 
of the fields in which telemedicine methods were pioneered and introduced into everyday practice. Some 
of these methods have already become standard procedures for diagnosis and treatment in some Polish 
centers, with other soon to follow. Clinical study results not only demonstrate reliability and usefulness 
of telemedicine technologies but also show that their use in clinical practice improves the patients’ 
prognoses and quality of life. Moreover, study results in highly developed countries show a potential 
cost-effectiveness of telemedicine from the perspective of healthcare systems. There is an unquestionable 
need to establish clear rules for telemedicine use in Poland, which would ensure their high quality and 
adequate clinical application. This paper is a summary of the current status of telemedicine solutions 
used in cardiology, with a particular focus on the Polish healthcare system, and presents both the commonly 







E X P E R T  O P I N I O N  A N D  P O S I T I O N  S T A T E M E N T
Telemedicine solutions in cardiology 
A joint expert opinion by the Information Technology and Telemedicine Committee 
of the Polish Cardiac Society, the Section of Noninvasive Electrocardiology 
and Telemedicine of the Polish Cardiac Society, and the Clinical Research 
Committee of the Polish Academy of Sciences (short version, 2021)
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the number of days lost due to hospital admis‑
sions or death and lowered all ‑cause mortality.6 
As a result, European experts in their 2019 con‑
sensus agreed for the first time that at ‑home 
telemonitoring may be considered in patients 
with heart failure.7 Another report emphasized 
the benefits of telemedical solutions in certain 
patient subgroups: such as nondepressive pa‑
tients with left ventricular ejection fraction of 
25% or greater and a history of decompensat‑
ed heart failure.8
Telecare may improve treatment outcomes 
in cardiovascular patients, both in terms 
of prognosis and prevention of treatment‑
‑related complications. The available telemed‑
icine tools help assess patient adherence to 
prescribed medication and recommended life‑
style changes. This is achieved by both mon‑
itoring the amount of remaining medication 
and assessing treatment efficacy based on vi‑
tal signs, such as blood pressure and heart rate, 
or body weight. The level of physical activity 
(for example during cardiovascular rehabilita‑
tion) can also be monitored (TABLE 1).
Some currently available applications help not 
only to passively monitor the use of medications 
but also have additional functions, such as alerts 
and reminders, if a medication has not been 
taken. The option of constant supervision over 
the patients’ drug regimen with the use of tele‑
medicine may play a key role in maximizing pri‑
mary and secondary prevention in major groups 
of cardiovascular patients: those with heart fail‑
ure, history of acute coronary event, atrial fi‑
brillation, and history of coronary intervention.
tele ‑education Tele ‑education is an attempt 
to address the needs of cardiovascular patients 
that remain unmet in the current healthcare sys‑
tem. For instance, patients may want to know 
more about and understand the causes and clin‑
ical manifestations of certain diseases, indica‑
tions for individual classes of drugs, cardiac im‑
plantable electronic device implantation, and 
invasive procedures. Thus, tele ‑education in‑
creases the odds of the patients’ active partici‑
pation in prevention, rehabilitation, diagnostic 
procedures, and treatment. The importance of 
paper is a summary of the current status of tele‑
medicine solutions used in cardiology, with a par‑
ticular focus on the Polish healthcare system.
The authors of this paper established a set of 
guidelines for individual telemedicine proce‑
dures based on the European Society of Cardi‑
ology (ESC) Recommendations for Guidelines 
Production. The resulting guidelines have been 
classified into the following categories: “is rec‑
ommended / indicated” (I), “should be consid‑
ered” (IIa), “may be considered” (IIb), and “is 
not recommended” (III).
telecare Telecare involves the application of 
various forms of patient care with the use of 
telemedicine tools at the patient’s place of resi‑
dence. Telecare complements direct (in ‑person) 
healthcare services. Its main goal is to improve 
patient compliance, to detect possible exacer‑
bations early, and to detect any conditions that 
may aggravate the course of the patients’ cur‑
rent disease. The broad term “telecare” encom‑
passes the use of any diagnostic methods and 
tools described below.
Telecare, with its fundamental components 
of teleconsultations and remote treatment mon‑
itoring, is generally used to complement in‑
‑person healthcare. Observational studies in 
a group of over 4000 patients with a history of 
acute coronary syndrome showed that the pos‑
sibility of contacting a medical call center in 
case of concerning symptoms significantly low‑
ered the annual mortality rate in comparison 
with that in the control group.4 Studies evalu‑
ating the impact of telemedical solutions on im‑
proving care of patients with heart failure have 
yielded inconclusive results. A number of pro‑
spective clinical studies showed no significant 
effect of teleconsultations or telecare on the re‑
hospitalization rate or prognosis in patients 
with heart failure.5 However, the TIM ‑HF2 (Ef‑
ficacy of Telemedical Interventional Manage‑
ment in patients with Heart Failure) study has 
been a breakthrough.6 The study employed mon‑
itoring of blood pressure, electrographic pa‑
rameters, body weight, and clinical symptoms 
in a group of 1571 patients with heart failure 
and revealed that this form of care reduced 
Table 1 Summary of indications for the use of telecare and tele ‑education
Recommendations Level
The use of telecare to some extent and in those selected cases where it would be an important adjunct to 
standard healthcare, eg, in a subset of patients with heart failure, in patients scheduled to undergo 
a therapeutic intervention (to optimize preparedness for the elective procedure)
I
Remote modifications to the medication regimen if specific safety conditions are met: ie, the medication was 
already used before and caused no side ‑effects at the recommended dose or the risk of such side ‑effects is 
low, it is possible to convey the recommendation to the patient in an unambiguous way that can be easily 
understood, and the effects of the change in treatment can be assessed, eg, via vital signs monitoring
IIb
Tele -education as one of the forms of education for any cardiovascular patients I
A telecare system that is comprehensive and consistent with the general healthcare model in the given country I
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an in ‑person contact between the parties at the 
time when the medical service is necessary or 
would help reduce the risk to the patient’s health.
Specialist consultations may have the form of:
•	 teleconsultations in an outpatient setting;
•	 urgent specialist consultations, for example, 
with the use of telemedicine systems installed 
at emergency facilities (electrocardiographic 
[ECG] data transmission);
•	 scheduled specialist consultations via tele‑
medicine tools, for example, between spe‑
cialists from tertiary reference centers and 
primary care physicians, cardiologists from 
secondary reference centers or specialist 
outpatient facilities, and specialists from 
other fields of medicine (text, teleconsul‑
tations, audio teleconsultations, and video 
teleconsultations);
•	 scheduled teleconsultations on the results of 
imaging studies (electrocardiography, echo‑
cardiography, ultrasonography, radiography, 
computed tomography, magnetic resonance 
imaging, coronary angiography, histological 
examinations, etc);
•	 teleconsultations as part of medical person‑
nel education programs (TABLE 2).
Key benefits of teleconsultations with special‑
ists are:
•	 increased accessibility of consultations and 
an optimal utilization of medical personnel 
resources;
•	 rapid diagnosis and help in cases of emergency;
•	 time and cost savings and increased opera‑
tional efficiency;
•	 epidemiological safety;
•	 the possibility of including any number of 
persons, who are at different locations, in 
the consultation.
Key limitations of teleconsultations:
•	 teleconsultation participants have to have 
medical equipment that ensures high ‑quality 
recording of biological signals, adequate com‑
puter parameters, software, and tools for 
high ‑quality transmission of data;
•	 healthcare personnel have to be qualified, also 
in terms of using telemedicine technologies;
•	 ensuring personal data protection and legal 
personal data processing is necessary;
tele ‑education in therapy (for example for pa‑
tients with heart failure) is due to the crucial role 
of self ‑care for long ‑term prognosis. Moreover, 
studies showed that a significantly higher pro‑
portion of patients after myocardial infarction, 
educated via repeated telephone calls after their 
hospital discharge, exhibit healthy behaviors, 
such as increased physical activity and smoking 
cessation.9,10 The fact that tele ‑education tools 
can be used repeatedly gives the patient an op‑
portunity to learn from experts at his or her 
own pace. The Polish Cardiac Society offers pa‑
tients tele ‑education through the following web‑
sites: www.slabeserce.pl, www.copozawale.pl, 
www.arytmiagroziudarem.pl, and www.copo‑
zatorze.pl.
Comprehensive patient tele ‑education can 
be also achieved via mobile phone applications, 
which offer several forms of educational sup‑
port. These applications may include multimedia 
presentations about the underlying disease that 
causes the patient’s symptoms and the treatment 
methods (including visualization of medical pro‑
cedures). These applications remind patients to 
take their medications and record the fact of 
taking each medication; some offer individual 
behavioral education; and some allow the pa‑
tient to ask a question of a medical team via text 
communication or a videoconference. They also 
remind the patients to follow nonmedication‑
‑related recommendations and offer automatic 
assessment whether they are followed or not (eg, 
an increase in physical activity) (TABLE 1).
teleconsultations Teleconsultations are 
a form of remote medical consultations between 
healthcare professionals or between a health‑
care professional and a patient who are at dif‑
ferent locations. Teleconsultations are held with 
the use of modern technologies of text, verbal, 
and imaging data transmission for diagnostic, 
therapeutic, rehabilitation, educational, and ef‑
fectiveness assessment purposes.
Teleconsultations in the form of text, ver‑
bal, or image communications may be achieved 
via a cellular phone network or internet ‑based 
communications system. The key indication 
for the use of this healthcare service is lack of 
Table 2 Summary of indications for the use of teleconsultations
Recommendations Level
Teleconsultations (text consultations, video consultations, video consultations with medical data 
transmission) between healthcare professionals in cases raising therapeutic or diagnostic questions
I
Teleconsultations between healthcare professionals and patients to optimize patient care in situations 
where this form of consultation helps reduce the risk to the patient’s health resulting from limited 
access to in -person consultations and if the procedure meets the commonly accepted principles of good 
clinical practice
IIa
Teleconsultations as one of the available options to provide specialist care in patients in a stable 
condition who continue their care at a given specialist outpatient clinic, and the procedure is performed 
in accordance with the principles of good clinical practice
IIa
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the appropriate event button.15-17 The preferred 
tool are external event recorders, which are 
placed on the patient’s chest along with the elec‑
trodes and leads, and operate as external loop 
recorders (ELRs),14 -16,18,19 which makes it possi‑
ble to obtain ECG recording including a pre‑
‑specified period preceding the  pressing of 
the event button. In other cases that may also 
be considered, the symptoms have to last long 
enough for the device to be attached and acti‑
vated. State ‑of ‑the ‑art options include systems 
that are based on ECG recording modules inte‑
grated into smartphones. Event ‑based ECG re‑
cording and immediate data transmission to 
the monitoring center via a cellular network are 
possible due to electrodes integrated into the de‑
vice, which is then placed against the surface of 
the patient’s body.14 There are also external de‑
vices that can record a 30‑second to 3‑minute 
electrical activity of the heart and operate when 
the recording device—which transfers the data 
to a mobile phone application—is held against 
the chest wall. These data may be converted into 
a file and sent via an email. Such devices may be 
used by patients or by physicians, for example 
during a home visit.20
One particular form of remote ECG moni‑
toring is the use of implantable loop record‑
ers (ILRs).14 These devices are intended for pa‑
tients whose symptoms occur very rarely, and 
for whom carrying an external device for so long 
would be impossible. Implantable loop recorders 
may operate in an automatic mode or react to 
the patient’s command. They also include a ret‑
rospective memory function (and retain data 
for the length of time, or loop length, specified 
by the doctor), and transmit data to the consul‑
tation center. One recent form of remote ECG 
monitoring are external devices in the form of 
patch ECG monitors (or PEMs, involving adhe‑
sive electrodes), which can continuously record 
the electrical activity of the heart for up to 14 
days. The obtained recording is subsequently 
analyzed by an automatic abnormality detec‑
tion algorithm.13,16 Schultz et al21 demonstrated 
that prolonged monitoring via a PEM doubles 
the chances of detecting arrhythmia in com‑
parison with a 48‑hour recording. Early PEMs 
were only capable of recording single ‑lead ECG; 
however, continued research into this technolo‑
gy may soon allow multi ‑lead recordings, which 
should help improve recording quality and its 
diagnostic value.
The most recent ESC atrial fibrillation (AF) 
guidelines set at 30 seconds the minimum du‑
ration of an ECG recording sufficient for an ex‑
pert skilled in the ECG interpretation to diag‑
nose AF.22 However, what remains problemat‑
ic is differentiating AF with other arrhythmias 
(eg, supraventricular ectopic beats) or conduc‑
tion blocks, which may be impossible in the case 
of a single ECG tracing. In light of the possible 
•	 there is no in ‑person contact with the patient, 
along with its associated consequences, in‑
cluding the necessity to reliably confirm pa‑
tient identity and having the patient confirm 
his or her understanding of remotely issued 
recommendations.
Another important aspect to consider is 
the fact that some patients may consider a re‑
mote contact with a physician to be inferior to 
a direct examination. The doctor’s body language 
is an important nonverbal aspect of communi‑
cation, building trust, and establishing rapport. 
Thus, a preferred form of teleconsultations be‑
tween healthcare professionals and patients are 
video teleconsultations.
The coronavirus disease 2019 (COVID‑19) pan‑
demic required rapid and widespread introduc‑
tion of teleconsultations in outpatient settings. 
As early as on March 12, 2020, the Polish Nation‑
al Health Fund approved conducting medical 
appointments via teleinformation systems (or 
other communications systems) in patients con‑
tinuing their care at a given specialist outpatient 
clinic.11 This solution helped, to a large extent, 
avoid interruptions in specialist medical services 
and offered care continuity for chronically ill pa‑
tients, while ensuring the epidemiological safe‑
ty of both the patients and medical personnel. 
A number of guidelines and procedures for con‑
ducting teleconsultations were developed and 
implemented; this includes the manuals issued 
by the Telemedicine Task Force Foundation.12
remote electrocardiographic monitoring 
Technical parameters, operational principles 
Remote ECG monitoring via external record‑
ing devices is the basic telediagnostic tool used 
in cardiology, especially in the area of arrhyth‑
mia.13 Remote ECG monitoring involves analy‑
sis of electrocardiograms obtained remotely and 
transferred to the monitoring center. Remote 
ECG monitoring helps detect, document, and 
assess abnormal electrical activity of the heart 
during daily activities and increases the chanc‑
es of establishing an accurate diagnosis. Some 
remote ECG monitoring devices can additional‑
ly monitor the respiratory rate, physical activi‑
ty, and blood pressure.14
Patient ‑initiated transmission of short, event‑
‑based ECG (event recording of a single ‑lead ECG 
of at least 30 seconds in duration) may be used 
in the following circumstances:
•	 at the time when the patient develops symp‑
toms suggesting arrhythmia, a conduction 
block, or ischemia;
•	 in circumstances that could trigger an ar‑
rhythmia, conduction block, or ischemia;
•	 in other circumstances selected by the pa‑
tient and / or at specific fixed time points de‑
fined by the doctor.
In event ‑based Holter devices, the recording 
function is activated by the patient by pressing 
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Indications for remote electrocardiographic 
monitoring  The indications for remote ECG 
monitoring in the diagnostic workup of cardi‑
ac patients are directly related to the benefits of 
this technique over standard ECG monitoring 
(TABLE 3).18,22-34 We would like to emphasize that in 
the case of frequent symptoms (occurring dai‑
ly or several times a week), conventional ambu‑
latory ECG monitoring (Holter), which in prac‑
tice can be used for continuous monitoring for 
up to 72 hours, should be the diagnostic method 
of choice.34 In the case of indications for an ECG 
assessment over a period longer than 14 days, 
the preferred diagnostic method should be re‑
mote ECG monitoring. One of its types, event‑
‑based remote monitoring, is intended particu‑
larly for patients with sporadic symptoms (oc‑
curring less than once a month) or those who 
require ECG monitoring in highly specific situa‑
tions, and the transmission of ECG data may be 
scheduled according to a predetermined time‑
table (eg, cardiac rehabilitation, selected clini‑
cal situations, or circumstances associated with 
the patient’s physical activity). The decision to 
initiate remote ECG monitoring has to be made 
based on the patient’s condition, socioeconomic 
conditions, and the results of earlier diagnostic 
evaluations. Remote ECG monitoring is not rec‑
ommended in patients with typical symptoms 
(eg, angina pectoris, frequent palpitations), who 
had not undergone first ‑line diagnostic investiga‑
tions (eg, cardiac stress test / coronary angiogra‑
phy, 24‑hour Holter ECG monitoring).35
Remote ECG monitoring is used primarily 
in the diagnostic workup of arrhythmia, both 
in symptomatic and asymptomatic patients. 
One specific group are patients with a histo‑
ry of transient ischemic attack (TIA) due to 
(an often previously undetected) arrhythmia. 
Cardiac embolism is one of the most common 
mechanisms of ischemic stroke, with a 10% to 
20% risk of TIA recurrence within 90 days.17,36,37 
Therefore, demonstrating that a given embol‑
ic event was arrhythmia induced is crucial for 
secondary prevention (ie, anticoagulant treat‑
ment initiation).17,38 Remote ECG monitoring im‑
proves the chances of detecting arrhythmia and 
at the same time reduces time to diagnosis.24,34 
Detecting AF is of particular importance in pa‑
tients with high CHA2DS2‑VASc scores, since 
they are at high risk of developing thromboem‑
bolic complications.39 A systematic review and 
meta ‑analysis by Sposato et al40 demonstrated 
that remote ECG monitoring in patents after 
a stroke or TIA helps to diagnose new ‑onset AF 
in 16.9% of patients in comparison with 10.9% 
of patients diagnosed via conventional Holter 
monitoring. A meta ‑analysis by Dussault et al34 
showed that longer ECG monitoring in post ‑TIA 
patients is associated with significantly higher 
chances of AF detection. Monitoring for up to 
72 hours helped detect arrhythmias in 5.1% of 
complications of AF treatment (including med‑
ications increasing the risk of bleeding) it is ad‑
visable to be cautious when interpreting record‑
ings from a single ‑lead ECG.
Mobile device ‑based technologies (smart‑
phones and smartwatches) are also increasing‑
ly popular. They help assess the heart rate and, 
in selected cases, ECG tracings. Some of these 
functions require active initiation by the patient, 
with some capable of monitoring the pulse and—
if any irregularities are detected—automatical‑
ly transmitting an ECG recording.13,22 The pau‑
city of scientific data showing the effectiveness 
of these methods in detecting AF has been em‑
phasized, and further studies are required to 
assess the clinical usefulness of these technol‑
ogies. Moreover, the risk of overdiagnosis and 
the associated unnecessary decisions to intro‑
duce treatment should be taken into consider‑
ation. It is also important to consider the psy‑
chological aspect of long ‑term monitoring via de‑
vices prone to generating large numbers of false‑
‑positive alarms and thus inducing the feelings 
of fear and uncertainty in patients.13,22
Transmission of short event ‑based ECG re‑
cordings by medical personnel is a typical part 
of teleconsultation, which may be also used in 
emergency medical services and as part of co‑
operation between higher ‑level specialist facil‑
ities and both primary care and lower ‑level re‑
ferral facilities.16,23
The transfer of continuous ECG recording 
with the option of online analysis is an ad‑
vanced method that makes it possible to analyze 
the complete uninterrupted ECG recording. Such 
a recording may be sent online to a monitoring 
center in real time or at a later time. The devel‑
opment of intelligent recording and analysis 
systems has been a breakthrough in that these 
systems can classify QRS complexes as normal, 
supraventricular, or ventricular depending on 
arrhythmic complexity. Automatic detection 
of important ST ‑segment changes is also pos‑
sible. Transmission of any detected abnormali‑
ties to the monitoring center is automatic (auto‑
‑triggered recording), with an additional possi‑
bility of alerting the given patient and / or phy‑
sician (via a sound signal or text message).11,24-26 
The diagnostic effectiveness of these automated 
systems is undoubtedly going to improve with 
the use of more and more advanced data analy‑
sis methods, including machine learning.27
Wristband optical heart‑rate monitors are 
a user ‑friendly solution; however, only adequate‑
ly validated devices should be used this way. 
Another promising solution are smartphone‑
‑integrated devices, which can record single‑
‑lead ECG. However, they have only been used as 
purely preliminary diagnostic tools, with the rec‑
ommended course of action involving confir‑
mation of the diagnosis with an at least 2‑lead 
ECG recording.28
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Technological advances in the field of mobile 
devices are associated with new functions of 
smartwatch‑ / smartphone ‑type devices. Their 
use helps identify patients with suspected AF. 
The  Apple Heart study conducted in nearly 
420 000 smartwatch users identified irregular 
pulse in 0.5% of the study population, and 34% 
of those were diagnosed with AF via a week ‑long 
continuous monitoring with PEMs.43 However, 
the optimal duration of monitoring with smart‑
phones / smartwatches has not been established, 
patients, whereas 3‑month remote ECG mon‑
itoring yielded this diagnosis in nearly one‑
‑third of the study population. Based on these 
results, the optimal duration of monitoring 
should be 30 days or longer, which is consistent 
with the American Heart Association / Ameri‑
can College of Cardiology / Heart Rhythm Soci‑
ety (AHA / ACC / HRS) recommendations.41 How‑
ever, it is important to note that in most cas‑
es, the diagnosis can be established after only 
a week of monitoring.10,42
Table 3 Summary of the indications for remote electrocardiographic monitoring
Recommendations Level
Continuous (or event ‑based) remote ECG monitoring in patients with suspected clinically relevant 
paroxysmal arrhythmia undocumented in earlier assessments (resting ECG, 24–72h Holter ECG), with 
a preference towards event ‑based remote ECG monitoring in sporadic (less than once per month) symptoms
I
Continuous (or event ‑based) remote ECG monitoring in patients after ischemic stroke, with negative history 
of arrhythmia and no confirmation of arrhythmia in previous assessments (resting ECG, 24–72 h Holter ECG)
IIa
Continuous (or event ‑based) remote ECG monitoring in patients with multifocal vascular lesions of 
the central nervous system, likely to be a result of embolism, with a negative history of arrhythmia, and 
with no arrhythmia shown in earlier assessments (resting ECG, Holter ECG)
IIb
Continuous remote ECG monitoring after ablation procedures for arrhythmias (mainly atrial 
fibrillation / flutter) to assess procedure effectiveness (including quantitative, ie, AF burden, assessment)
IIa
Continuous (or event ‑based) remote ECG monitoring in patients at high risk of life ‑threatening (especially 
ventricular) arrhythmias, eg, those at the early post ‑myocardial infarction period and those with heart failure
IIb
Remote ECG monitoring in patients with paroxysmal atrial fibrillation / flutter that is documented for 
the first time but likely to be secondary or sporadic.
IIb
Continuous (or event ‑based) remote ECG monitoring in patients diagnosed with atrial fibrillation / flutter to 
assess heart rate control in case of discrepancies between the results of earlier assessments (resting ECG, 
Holter ECG) and the reported symptoms, which suggest inadequate heart rate control in certain 
circumstances in patients with persistent AF or during episodes of paroxysmal AF
IIb
Continuous (or event ‑based) remote ECG monitoring to assess the sinus rhythm in case of discrepancies 
between the results of earlier assessments (resting ECG, Holter ECG) and the reported symptoms, which 
suggest inadequate heart rate control
IIb
Continuous (or event ‑based) remote ECG monitoring during the physical training that is part of early cardiac 
telerehabilitation
I
An ILR in patients with recurrent syncope of unknown origin if there is a chance of recurrence within 
the device’s battery life
I
An ILR in patients with recurrent syncope of unknown origin at high risk of adverse clinical events, whose 
earlier diagnostic assessments failed to provide a diagnosis and who have no indications for an implantable 
cardioverter ‑defibrillator and / or pacemaker as part of primary prevention
I
Continuous (or event ‑based) remote ECG monitoring in patients with syncope of unknown origin (eg, 
suspected cardiodepressive syncope, paroxysmal arrhythmias / conduction blocks, suspected or diagnosed 
treatment ‑refractory epilepsy), whose earlier assessments (resting ECG, Holter ECG) failed to show any 
association between clinical symptoms and ECG patterns
IIa
Continuous (or event ‑based) remote ECG monitoring and / or an ELR or ILR in patients with nonspecific 
paroxysmal symptoms (vertigo, tinnitus, poor exercise tolerance) of unknown origin, whose earlier 
assessments (resting ECG, Holter ECG) were negative for arrythmia.
IIa
Continuous (or event ‑based) remote ECG monitoring in patients with suspected atypical, non atherosclerotic 
ischemic heart disease (eg, caused by vasospasm)
IIa
Continuous (or event ‑based) remote ECG monitoring in patients after transcatheter aortic valve 
implantation considered for early hospital discharge but at a higher risk of developing a conduction block
IIb
Continuous (or event ‑based) remote ECG monitoring to assess antiarrhythmic treatment effectiveness in 
case of discrepancies between the results of earlier assessments (resting ECG, Holter ECG) and the reported 
symptoms, which indicate inadequate treatment effectiveness
IIb
Continuous (or event ‑based) remote ECG monitoring to assess the safety of potentially pro arrhythmic drugs 
(eg, antipsychotics, antidepressants, antineoplastic drugs, and some antibiotics)
IIb
Abbreviations: AF, atrial fibrillation; ECG, electrocardiography; ELR, external loop recorder; ILR, implantable loop recorder
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the environment. These artifacts may mimic ar‑
rhythmias, that is, produce pseudo ‑tachycardia, 
pseudo ‑bradycardia, or pseudo ‑pauses. These, in 
turn, lead to overdiagnosing (errors of commis‑
sion) but also to underdiagnosing clinically rel‑
evant arrhythmias (errors of omission).14 Hence 
the warranted preference for at least 2‑lead re‑
cordings, patient education, and selecting the re‑
mote ECG monitoring devices best suited to 
the particular patient’s abilities and skill in us‑
ing them.
It is important to remember that ECG record‑
ings obtained via remote ECG monitoring do not 
have all 12 leads of the standard ECG, which 
is responsible for certain limitations of these 
methods in definitive diagnosis of the origin of 
some arrhythmias, such as wide QRS complex 
arrhythmias. Although long ‑term ECG record‑
ing is of limited use in the diagnostic workup of 
myocardial ischemia, the co ‑occurrence of docu‑
mented signs of ischemia and characteristic clin‑
ical symptoms may call for invasive diagnostic 
procedures for myocardial ischemia.
Organizational aspects of remote electrocardiogra­
phy monitoring The optimal solution is a 24/7 
surveillance of recordings obtained via remote 
ECG monitoring. The head of the facility offer‑
ing remote ECG monitoring should be a special‑
ist in cardiology and have experience in analyz‑
ing long ‑term ECG recordings. Each facility of‑
fering such services should have protocols (ap‑
proved by the head of the clinic / department / fa‑
cility) for dealing with situations when a patient 
is at risk and a medical center has to be contact‑
ed immediately. These protocols should clearly 
define the scope of responsibility of the persons 
conducting ECG surveillance and be adapted to 
each specific ECG monitoring method.
Patient preparation for remote ECG monitor‑
ing should involve detailed training in the use 
of the recording device, proper adhesive elec‑
trode placement, and a preset ECG recording 
schedule. The forms of communication between 
the patient and the monitoring center as well as 
the management of health ‑related emergencies 
have to also be established. In life ‑threatening 
situations, the supervising personnel has to have 
the means of immediately notifying the patient 
and / or the patient’s family and / or emergency 
medical services.
remote cardiac implantable electronic de‑
vice monitoring Remote cardiac implantable 
electronic device (CIED) monitoring involves 
a cardiac pacemaker or implantable cardioverter‑
‑defibrillator (ICD) whose functions allow for re‑
mote transmission of acquired data. These sys‑
tems operate thanks to a transmitter (provided 
to the patient) that transfers data from the im‑
planted device memory to the monitoring cen‑
ter via a telecommunications network. Moreover, 
and the prognostic significance of silent atrial 
fibrillation remains unknown.13,22
Remote ECG monitoring is also the most 
effective tool for assessing whether ablation 
treatment for arrhythmia has been success‑
ful.5,9,10,14 -17,44,45 Although the optimal moment 
of recording initiation and its duration in such 
cases should be determined on an individual 
basis, the authors of the relevant recommenda‑
tions suggest using remote ECG monitoring not 
earlier than 3 months following ablation and for 
anywhere from 1 to 4 weeks.
Remote ECG monitoring may be consid‑
ered for identifying patients at risk of complex 
ventricular arrhythmia,33 particularly those 
in the early post ‑myocardial infarction peri‑
od, those with heart failure, hypertrophic car‑
diomyopathy, and arrhythmogenic right ven‑
tricular dysplasia.15,17,46 In those patients, re‑
mote ECG monitoring may provide decisive ar‑
guments for making the final therapeutic deci‑
sion. The optimal monitoring duration in these 
patients should be at least 30 days, or shorter if 
arrhythmia is detected.
Remote ECG monitoring is also an effective di‑
agnostic tool for syncope of unknown origin (eg, 
suspected cardiodepressive syncope, suspected 
paroxysmal arrhythmias / conduction blocks, 
suspected or diagnosed treatment ‑refractory ep‑
ilepsy).17,18 The optimal solution in patients with 
symptoms occurring less than once a month is 
ILR.18 A meta ‑analysis of 5 randomized studies 
conducted in patients with syncope of unknown 
origin indicated ILR superiority over conven‑
tional diagnostic strategies with the use of ex‑
ternal recorders, tilt testing, and electrophysi‑
ology studies. The use of ILRs increased the rel‑
ative likelihood of establishing a diagnosis and 
was cost ‑effective.47,48
Remote ECG monitoring may be also consid‑
ered in the assessment of patients with non‑
specific symptoms, which could be caused by 
undiagnosed arrhythmias, conduction blocks, 
or ischemia.17,31,49 The method is a useful tool 
for monitoring patients after structural heart 
procedures (eg, transaortic transcatheter aor‑
tic valve implantation),50 for monitoring the ef‑
fectiveness of antiarrhythmic treatments and 
the safety of proarrhythmic drugs (eg, selected 
anti ‑infectives, antidepressants, psychotropic 
agents, and antihistamines) and antiarrhythmic 
drugs of potential pro arrhythmic effects, with 
a particular focus on bradycardia and tachycar‑
dia and QT interval assessment.15,18,51
Key limitations of remote electrocardiographic mon­
itoring The most important limitation of re‑
mote ECG monitoring are ECG tracing artefacts, 
which are most commonly associated with body 
movements, poor electrode adhesion, conducting 
wire dysfunction, action potentials in skeletal 
muscles, and electromagnetic interference from 
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conditions of transmission. One very useful 
functionality that became available recently al‑
lows for transmission of intracardiac signal re‑
cording acquired via an ICD; this data transmis‑
sion is initiated by the monitoring center. Once 
a connection is initiated, the transmission oc‑
curs nearly in real time (with a 2–3‑minute de‑
lay, depending on the speed of transmission).
According to an HRS expert consensus52 sup‑
plementing patient care with remote CIED mon‑
itoring is superior to the model of care based 
solely on standard prescheduled in ‑person ex‑
aminations. Remote CIED monitoring should be 
offered to every patient as part of routine care. 
An in ‑person visit at a specialist clinic where 
these devices can be assessed is recommended 
(depending on the clinical situation) within 2 
to 12 weeks after device implantation, and once 
a year thereafter. The HRS consensus also em‑
phasized the importance of remote CIED mon‑
itoring if any of the components of the CIED 
becomes subject to recall. In such situations, 
remote monitoring allows for early detection 
of any malfunction of the recalled component.
ESC recommendations stipulate that re‑
mote monitoring of CIEDs with an atrial elec‑
trode may help record atrial high ‑rate episodes 
(AHREs), some of which may be AF (TABLE 4). De‑
tection of AHRE alone is insufficient to diagnose 
AF but may prompt active diagnostic efforts. Ac‑
cording to guidelines, definitive diagnosis re‑
quires AF to be recorded in 12‑lead surface ECG 
or an at least 30‑second single ‑lead recording.22 
The question whether AHRE detection in the de‑
vice’s memory is an indication for anticoagulant 
treatment in stroke prevention remains unan‑
swered,53 therefore each case should be consid‑
ered individually with respect to AHRE duration 
and thromboembolic risk. An estimated risk of 
stroke in patients with AHREs is lower than in 
those diagnosed with AF, and the co ‑occurrence 
of stroke and AHRE / silent AF is uncertain.13,22 
There are ongoing studies that assess the ratio‑
nale of oral anticoagulant use in patients with 
an AHRE of 6 minutes or longer.54
In accordance with the IN ‑TIME (Implant‑ 
‑based Multiparameter Telemonitoring of Pa‑
tients with Heart Failure) trial methods and 
recent months saw an introduction of this func‑
tionality in mobile phones that can use Blue‑
tooth technology to connect with the implanted 
device. In those cases, the patient does not need 
an additional transmitter for data transmission.
Current cardiac pacemakers and ICDs store 
data on battery status, electrode parameters, 
pacing effectiveness, detected arrhythmias, and 
selected parameters of the patient’s condition, 
including the cardiovascular status. Depend‑
ing on the system type, it may be possible to 
obtain periodic reports transmitted at prede‑
termined time points (the transmission may 
be automatic or patient ‑initiated) or continual‑
ly monitor the device, which involves automat‑
ic parameter assessment and alerting the moni‑
toring center of any irregularities (eg, electrode 
failure, battery depletion, arrhythmia, ineffec‑
tive pacing) (TABLE 4).
The frequency of transmissions and minimum 
scope of transferred data should be set individ‑
ually, considering the clinical situation (stabili‑
ty of the patient’s condition, frequency of treat‑
ment modifications, type of arrhythmias, rate of 
ICD interventions), CIED indications (primary or 
secondary prevention, pacemaker dependency), 
and CIED type (pacemaker, ICD, cardiac resyn‑
chronization therapy [CRT]). Data transmission 
should take place every 3 months (immediate‑
ly in case of an alert), which is more often than 
direct follow ‑up visits at the monitoring center 
recommended by experts52 (every 3–12 months 
for cardiac pacemakers and every 3–6 months 
for ICDs). Additionally, annual in ‑person exam‑
inations at the specialist clinic are recommend‑
ed to confirm correct device function, to check 
if the automatically measured pacing parame‑
ters are consistent with the measurements con‑
ducted by a physician, to update device settings, 
and to answer any patient questions.
The transmission should include basic infor‑
mation on the device’s function, such as battery 
status, device settings, lead pacing and imped‑
ance parameters, as well as any detected arrhyth‑
mia episodes. The scope of transferred data may 
be subject to certain limitations due to structur‑
al constrains of the individual devices (which 
vary between manufacturers) and the technical 
Table 4 Summary of the indications for cardiac implantable electronic device telemonitoring
Recommendations Level
Regular reading of data from CIED memory to detect AHREs and, once detected, further ECG monitoring to 
document atrial fibrillation
I
Remote CIED monitoring in conjunction with conventional in -person visits at least once a year, suggested to 
patients (in particular, to those with heart failure and left ventricular ejection fraction ≤35% to improve 
prognosis) as an alternative to the traditional healthcare model
I
Remote CIED monitoring in all patients with an implanted CIED with at least one component under recall, 
where this component’s malfunction may be directly life -threatening or cause a loss of an important 
functionality of the CIED
I
Abbreviations: AHRE, atrial high ‑rate episode; CIED, cardiac implantable electronic device
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centers, or state ‑reimbursement criteria for this 
health service have not yet been conclusively es‑
tablished. Nonetheless, there are ongoing efforts 
to establish these parameters, which is likely to 
make remote CIED monitoring available in Po‑
land as a service reimbursed from public funds. 
Currently, due to the COVID‑19 pandemic, rapid 
introduction of remote CIED monitoring is espe‑
cially important. It would help limit in ‑person 
contact between patients and healthcare pro‑
fessionals, and thus could significantly reduce 
the risk of infection.
Hybrid cardiac telerehabilitation Hybrid 
cardiac telerehabilitation is a form of rehabilita‑
tion that uses state ‑of ‑the ‑art data transmission 
technologies, which helps monitor and direct 
the patient’s physical training at any location 
(within a mobile phone network range and / or 
internet access).13 Stage I of hybrid telerehabili‑
tation is conducted in hospital or outpatient set‑
tings and typically lasts 1 to 2 weeks. Stage II 
(telerehabilitation) is conducted at the patient’s 
residence at any location (within the range of 
a mobile phone network) and typically lasts 8 
to 12 weeks.
The center conducting hybrid telerehabilita‑
tion should be equipped with a computer sys‑
tem (platform) that offers verbal contact with 
the patient; acquisition, analysis, and storage 
of data transmitted from peripheral devices; 
remote monitoring of peripheral device func‑
tion, and remote correction of device function. 
The mobile peripheral device carried by the pa‑
tient should allow for remote monitoring of ap‑
propriate parameters, verbal communication, 
and directing of the training session.
The monitoring mode (on ‑demand, automatic‑
‑sequential, or continuous) and the scope of 
monitored parameters depend on the type of 
rehabilitation and the patient condition (low, 
moderate, and high risk).65 Verbal contact should 
be ensured with any mode and at any moment 
of telerehabilitation.
The minimum requirements for heart rate 
and / or ECG monitoring are:
•	 sequential recording, including the beginning 
and end of the defined training phase (warm‑
‑up, exercise, and cool ‑down; and the peri‑
ods of exercise and rest in interval training),
•	 on ‑demand recording triggered by the patient 
or trainer (in case of concerning symptoms 
or specific circumstances).
On ‑demand recording should allow for 
loop recording. The monitored ECG recording 
should include at least 2 leads. Ideally, the fol‑
lowing parameters can also be monitored: oxy‑
gen saturation, respiratory rate, body temper‑
ature, blood glucose levels (from a glucose me‑
ter), and physical activity (accelerometer, pe‑
dometer). Apart from the monitoring function, 
telerehabilitation requires a possibility to direct 
results (level IIb), ESC guidelines for the diag‑
nosis and treatment of heart failure recommend 
the use of multiparameter telemonitoring of 
symptomatic patients via implanted ICD or CRT 
devices (TABLE 4).5 Remote monitoring has been also 
useful in heart failure patients with an implant‑
ed ICD or CRT device undergoing comprehensive 
cardiac rehabilitation, in order to assess the ef‑
fects of rehabilitation.55
Remote CIED monitoring significantly re‑
duces the time to medical intervention, both in 
the case of abnormal device function and in oth‑
er emergency situations.56,57 This practice showed 
benefits in the form of improved patient quali‑
ty of life and reduced frequency of medical ap‑
pointments due to heart failure exacerbation, ar‑
rhythmias, or ICD interventions.58,59 The ALTI‑
TUDE study60 conducted in a group of remote‑
ly monitored patients with an implanted pace‑
maker, ICD, or CRT system showed the relative 
risk of death declined by 50% in comparison 
with that in nonmonitored patients. However, 
the randomized IN ‑TIME trial, conducted in pa‑
tients with heart failure and an ICD or CRT de‑
vice, the monitored group showed significantly 
reduced all ‑cause mortality and cardiovascular 
mortality.61 Similar results were shown in the EF‑
FECT (Remote Monitoring Improves Outcome 
after ICD Implantation: the Clinical Efficacy in 
the Management of Heart Failure) study.62 These 
data indicate that remote CIED monitoring con‑
siderably contributes towards improving progno‑
sis in patients with heart failure. Another ben‑
efit of remote monitoring is the significant re‑
duction in the time needed to assess one patient 
at a specialist clinic. The mean duration of data 
transmission analysis is at least 2‑fold shorter 
than that of a conventional device interroga‑
tion.63 However, importantly, the effectiveness of 
telemonitoring requires patients’ rigorous adher‑
ence to the transmission schedule, a highly qual‑
ified monitoring team, and the use of advanced 
change ‑tracking algorithms. Inadequate control 
of these factors could have been the reason for 
the poor results of the study REM ‑HF (Remote 
Management of Heart Failure Using Implantable 
Electronic Devices), in which the advantage of 
CIED over standard care was not demonstrated 
in terms of total mortality and unplanned hos‑
pitalization due to heart failure.64
Introducing a system of remote CIED moni‑
toring in Poland would require establishing tele‑
monitoring centers staffed with suitably qual‑
ified personnel. The person assessing remotely 
acquired data should be experienced in manag‑
ing patients with ICD and CRT devices, includ‑
ing being skilled at evaluating intracardiac elec‑
trograms. Remote CIED monitoring in Poland is 
currently at a pilot stage and is conducted at iso‑
lated university centers. The organizational as‑
pects of remote CIED monitoring, requirements 
that have to be met by remote CIED monitoring 
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Applications for patients Mobile applications 
may serve as patient education tools or a way 
to store information on the patients’ condi‑
tion. Some devices may also facilitate contact 
with healthcare professionals, for example, in 
the form of videoconferences. Recent years saw 
the development of applications for patients, 
which help monitor their pulse with the use of 
the phone’s LED and camera acting as an opti‑
cal sensor. Some of these applications also have 
algorithms for detecting irregular heart rate, 
which may facilitate diagnosis of arrhythmias, 
including atrial fibrillation. Moreover, some 
smartwatches currently available on the mar‑
ket can record (single ‑lead) ECG and provide 
its automatic analysis, which may also contrib‑
ute towards detecting arrhythmias.22 Nonethe‑
less, further studies are required to determine 
the clinical usefulness of these solutions.
Applications for physicians One of the key types of 
applications for physicians are educational appli‑
cations, which allow access to systematized sourc‑
es of medical knowledge (eg, medical information 
sources, such as the established guidelines or sum‑
maries of product characteristics) and facilitate 
everyday practice (eg, medical calculators). There 
are also applications that record biological signals, 
such as motion (accelerometer), pulse, or electri‑
cal activity of the heart (ECG tracings).
Applications as medical devices If an application 
is used for diagnosis, treatment, or patient mon‑
itoring, or for disease prevention, it should be 
considered a medical device, and as such has to 
meet the requirements specified in the May 20, 
2010, Medical Device Act.75 Applications that 
serve as the basis for diagnostic and therapeu‑
tic decisions have to be obligatorily reported to 
the Polish Office for Registration of Medicinal 
Products, Medical Devices, and Biocidal Prod‑
ucts. This includes applications that use mobile 
devices for storing data acquired from sensors 
(ECG recording, electroencephalograms, eye 
movements, blood pressure, oxygen saturation), 
with the exception of educational applications, 
medical calculators, and devices used solely as 
a magnifying glass or sound amplifier, etc.
other telemedicine solutions used in car‑
diology An online patient management sys­
tem with the use of a wearable cardioverter­
‑defibrillator  Wearable cardioverter‑defibrilla‑
tors (WCDs), which are more and more accessible 
in Poland and worldwide, are capable of identifying 
the training sessions to help the patient com‑
plete the assigned individualized training pro‑
gram. The functionalities required for this pur‑
pose are:
•	 sound and / or light signaling of the beginning 
and end of the exercise phase and the begin‑
ning and end of the rest phase (for interval 
training) and
•	 sound and / or light signaling of failure to 
reach the desired heart rate acceleration or 
of exceeding the individually set maximum 
heart rate.
Hybrid telerehabilitation may be used as 
part of remotely monitored at ‑home rehabili‑
tation programs, in low‑, moderate‑, and high‑
‑risk patients (eg, with heart failure, after heart 
transplantation).66-68
The preferred form of physical exercise is con‑
tinuous / interval walking training, optimally, 
Nordic walking, including a warm ‑up, exercise, 
and cool ‑down phases (TABLE 5).65,69,70
Clinical indications and contraindications for 
telerehabilitation are the same as for conventional 
cardiac rehabilitation.65 However, essential quali‑
fying criteria for telerehabilitation are the patient’s 
consent and her or his ability to exercise alone and 
to cooperate remotely with the monitoring team. 
The condition required to initiate telerehabilita‑
tion is stable clinical condition (for at least 1 week 
in low‑ and moderate ‑risk patients, and at least 3 
weeks in high ‑risk patients).65
Telerehabilitation has not been shown to 
be dangerous. There were no reported deaths 
or noteworthy complications resulting from 
remotely monitored physical exercise.65,70 -7 3 
The safety of at ‑home ‑based cardiac telereha‑
bilitation depends on following the qualification 
requirements for such rehabilitation, observing 
contraindications to physical training, individu‑
alized planning of exercise sessions, patient ed‑
ucation, and—every time prior to a training ses‑
sion—completing a special procedure to quali‑
fy the patient as fit for rehabilitation (based on 
assessing the patient’s condition).65
The COVID‑19 pandemic made telerehabilita‑
tion the only possible intervention in many cas‑
es. Therefore, the European Association of Pre‑
ventive Cardiology identified cardiac telereha‑
bilitation as the optimal method of secondary 
prevention in the COVID‑19 era.74
Mobile applications Mobile applications are 
the software installed in mobile devices (smart‑
phones, tablets) or in external servers made ac‑
cessible via mobile devices.
Table 5 Indications for the use of telerehabilitation
Recommendations Level
Comprehensive hybrid cardiac telerehabilitation as a procedure equivalent to the conventional inpatient 
and / or an outpatient rehabilitation
I
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decompensation. Current ESC guidelines rec‑
ommend ambulatory pulmonary artery pres‑
sure (PAP) monitoring with a special sensor (Car‑
dioMEMS heart failure sensor, Abbott Vascu‑
lar) in symptomatic patients with heart failure 
previously hospitalized due to heart failure ex‑
acerbations (IIb) (TABLE 6).5 The CardioMEMS de‑
vice is implanted into the pulmonary circula‑
tion, with a Swan ‑Ganz intravascular cathe‑
ter used for its calibration. The device commu‑
nicates with an external system, which allows 
for remote transmission of PAP measurements. 
The CHAMPION (CardioMEMS Heart Sensor 
Allows Monitoring of Pressure to Improve Out‑
comes in NYHA Class III Heart Failure Patients) 
study demonstrated the safety of this procedure, 
with PAP monitoring ‑based treatment helping 
reduce the rate of hospitalizations for heart fail‑
ure exacerbations.78,79 The MEMS ‑HF (the Car‑
dioMEMS European Monitoring Study for Heart 
Failure) study confirmed these observations, ad‑
ditionally noting the benefits of CardioMEMS 
PAP monitoring in terms of quality of life and 
symptoms of depression.80 Another invasive 
method—right ventricular pressure monitor‑
ing (Chronicle 9520, Medtronic Inc.)—to assess 
systolic and diastolic right ventricular pressure, 
the first derivative of right ventricular pressure 
(dP/dt), and an estimated diastolic PAP, which 
corresponds to the left ventricular filling pres‑
sure.81 Moreover, left atrial pressure monitor‑
ing (HeartPOD, St. Jude Medical, currently Ab‑
bott Laboratories) is considered a potential in‑
dicator of left ventricular volume overload and 
pulmonary congestion.81
Hemodynamic parameters may be also mon‑
itored with bioimpedance methods. Intratho‑
racic impedance (ITI) is one of the parameters 
that may be monitored via implantable devic‑
es—the lower the value of impedance between 
the electrode and device case, the higher the fluid 
life ‑threatening ventricular arrhythmias, such 
as ventricular tachycardia or ventricular fibrilla‑
tion, and performing life ‑saving external defibril‑
lation.5,33,76 The use of WCDs may be indicated in 
several clinical situations involving patients after 
recent (<40 days) myocardial infarction and revas‑
cularization, with left ventricular ejection frac‑
tion of 35% or less, with myocarditis, with de novo 
heart failure, and potentially reversible causes of 
cardiomyopathy (peripartum, Takotsubo, heart 
failure in patients undergoing cancer therapy).77
Telemonitoring with the use of a WCD in‑
volves a patient data management system (Life‑
Vest Network) that includes clinical and device 
function data, such as arrhythmia events lead‑
ing to an intervention or those resolving spon‑
taneously. The system allows for monitoring 
many WCD function parameters, such as WCD 
technical parameters, WCD malfunctions, and 
the number of hours the patient wore the WCD 
in compliance with the recommendations.
Tele ­echocardiography Tele ‑echocardiography 
may involve recording echocardiography images 
and videos, their transmission to the monitoring 
facility in real time or at a later time, data analysis 
by teleconsultants, and transmission of their com‑
ments. This method may be useful for both elective 
and emergency assessments, ensuring specialist 
support in interpreting the echocardiography im‑
ages of technically difficult patients (TABLE 6). Tele‑
‑echocardiography can be performed with the use 
of portable devices (point ‑of ‑care echocardiog‑
raphy). Also available are miniaturized pocket‑
‑sized echocardiography devices and smartphone‑
‑compatible echocardiography probes that can be 
connect with a smartphone via a micro ‑USB.
Hemodynamic monitoring Hemodynamic mon‑
itoring is particularly important in patients 
with advanced heart failure at  high risk of 
Table 6 Summary of indications for the use of tele ‑echocardiography and telemonitoring of hemodynamic 
and other clinical parameters
Recommendations Level
A wireless hemodynamic monitoring system (CardioMems) in symptomatic patients with heart failure, 
previously hospitalized for this reason, in order to lower the risk of rehospitalization
IIb
State -of -the -art methods of invasive hemodynamic monitoring, such as measuring right ventricular 
pressure, left atrial pressure, and / or thoracic fluid content via transthoracic impedance (as a mobile device 
functionality) in individual cases of heart failure if the potential benefits of using these methods outweigh 
the risks associated with their use, and the outcomes of this form of telemonitoring are clinically verified.
IIb
Telemonitoring of the basic parameters of cardiovascular function (heart rate, blood pressure, body weight) 
and markers of treatment effectiveness in other chronic conditions (eg, capillary blood glucose in diabetes, 
respiratory function parameters) in patients in whom such telemonitoring may help improve these 
parameters.
IIb
Tele ‑echocardiographic examination in technically difficult cases (poor visualization, complex myocardial 
pathology) as part of scheduled teleconsultations if a remote assessment by a specialist may significantly 
affect further diagnostic and therapeutic decisions.
IIb
Tele -echocardiography as part of urgent teleconsultations in patients with a life -threatening condition (eg, 
acute coronary syndrome, acute aortic syndrome, cardiac tamponade) if a remote assessment by a specialist 
may significantly affect further diagnostic and therapeutic decisions.
IIb
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Act of December 5, 1996 (article 42 section 1) 3 
“A medical practitioner provides an opinion on 
the health condition of the given individual af‑
ter examining that individual in person or via 
teleinformation or communications systems.” 
The use of teleinformation tools over the course 
of treatment is also mentioned in the Medical 
Code of Ethics,97 article 9 of which reads “[a] 
medical practitioner may undertake treatment 
only after examining the patient. This does not 
apply to circumstances where medical advice 
can be only provided remotely,” and the deci‑
sion on whether the service may be provided re‑
motely is always at the discretion of the medical 
practitioner and cannot be influenced by sub‑
jective opinions of other parties. Nonetheless, 
telehealth services has to involve patient assess‑
ment in the form of obtaining a medical history.
The option of providing healthcare services with 
the use of teleinformation means of transmission 
may also help minimize health risks in the peri‑
od of epidemiological threat or an epidemic, such 
as the COVID‑19 pandemic. The decision to pro‑
vide a healthcare service with the use of telein‑
formation technologies or other communications 
systems is always at the discretion of the medical 
practitioner, who makes the initial assessment of 
the patient’s condition, current needs, and other 
parameters that are significant to ensure appro‑
priate treatment. In the case of patients who re‑
ceive treatment remotely, the medical practitioner 
is obligated to inform the patient of the necessity 
to visit a doctor or emergency room if their condi‑
tion worsens or in situations requiring direct (in‑
‑person) doctor ‑patient contact.
Offering remote healthcare services is asso‑
ciated with transmission of patients’ person‑
al data, including data on patients’ health sta‑
tus. Article 4 section 15 of the 2016/679 Regu‑
lation of the European Parliament and Council 
on the protection of natural persons with regard 
to the processing of personal data and the free 
movement of such data (further referred to as 
GDPR [General Data Protection Regulation]) 
from April 27, 2016, reads: “‘data concerning 
health’ means personal data related to the phys‑
ical or mental health of a natural person, in‑
cluding the provision of health care services, 
which reveal information about his or her health 
status.” The GDPR requires data encryption or 
pseudonymization and implementing appropri‑
ate measures to ensure ongoing confidentiality, 
integrity, availability, and resilience of process‑
ing systems and services, as well as regular test‑
ing, assessing, and evaluating the effectiveness 
of technical and organizational measures for en‑
suring the security of the processing. Healthcare 
professionals are allowed to use for their remote 
work tools and materials that were not provided 
by the employer; however, this is conditioned on 
respecting and protecting confidential informa‑
tion and other legally protected secrets.
content of the evaluated tissue.82 After over a de‑
cade of inconclusive studies on the prognostic 
usefulness of the parameters calculated based 
on ITI, there have recently been some encour‑
aging reports. The PARTNERS HF (Program to 
Access and Review Trending Information and 
Evaluate Correlation to Symptoms in Patients 
With Heart Failure) study83 evaluating tissue 
fluid content monitoring with OptiVol / Care‑
Link (Medtronic, Inc., Minneapolis, Minnesota, 
United States) used a complex prognostic algo‑
rithm (based on ITI, heart rate, heart rate vari‑
ability, AF burden, CRT pacing, ICD shocks, and 
patient activity), which helped predict the risk 
of hospitalization due to fluid overload within 
a 30‑day follow ‑up. Similarly encouraging results 
were also reported by other authors.84,85 There 
have been also promising reports on the use of 
mobile devices in monitoring fluid status via 
noninvasive bioimpedance ‑based solutions.86-88
Monitoring of other clinical parameters  Tele‑
monitoring is also used to remotely monitor 
a number of parameters (typically measured 
automatically) associated with chronic diseas‑
es co ‑occurring with cardiovascular disease 
(blood glucose levels in diabetes, lung function 
parameters in chronic obstructive pulmonary 
disease or asthma, etc).89-90 These methods are 
usually well tolerated by patients, help achieve 
therapeutic goals, and increase patient health 
awareness and involvement in the treatment 
process89,91,92 (TABLE 6).
Legal aspects of healthcare services with 
the use of telemedicine tools The hallmark 
of telemedicine are situations where a health‑
care service is being provided by healthcare pro‑
fessionals who, at that moment, are not at the 
same location as its recipients.93-95
Currently, the legal basis for providing health‑
care services with the use of teleinformation 
technologies in Poland is the Medical Activities 
Act (UoDzL),96 article 3 item 1 of which reads 
“Medical activities involve providing healthcare 
services. These services may be provided via 
teleinformation or communications systems”. 
Teleinformation tools or communications sys‑
tems may be also used to promote healthy behav‑
iors, achieve didactic goals, and foster research, 
including introduction of new medical technol‑
ogies and treatment methods (UoDzL, article 3 
section 2 items 1–2).96 Currently,  the law per‑
mits providing health services with the use of 
teleinformation tools, not only in hospital set‑
tings but also in outpatient settings (UoDzL, ar‑
ticle 24 section 2a).96
An amendment to Medical and Dental Prac‑
titioners Act has permitted the use of telein‑
formation means of transmission for the diag‑
nosis, treatment, and rehabilitation purposes. 
According to Medical and Dental Practitioners 
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summary Telemedicine is a rapidly develop‑
ing form of medical activity and part of medi‑
cal industry, with advanced technologies already 
available in Poland, notably, along with substan‑
tial involvement of domestic capital and engi‑
neering ideas.
Cardiology is one of the fields where telemedi‑
cine methods were pioneered and introduced into 
everyday practice. Some of these methods have 
already become standard procedures for diagno‑
sis and treatment in some Polish centers, with 
other ones soon to follow. Clinical study results 
not only demonstrate reliability and usefulness 
of telemedicine technologies, but also show that 
their use in clinical practice improves the pa‑
tients’ prognoses and quality of life, including im‑
proved patient survival (in the case of telemoni‑
toring in patients with an implanted CRT device). 
Moreover, study results in highly developed coun‑
tries show a potential cost ‑effectiveness of tele‑
medicine from the perspective of healthcare sys‑
tems.98,99 Such cost ‑effectiveness is due in part 
to the provision of specialist care to multiple 
persons simultaneously, optimizing the use of 
time by the personnel of high ‑level referral cen‑
ters, and effective coordination of the diagnos‑
tic / therapeutic process.
Currently, the most important limitation 
to the use of telemedicine in Poland is the lack 
of state reimbursement for most telemedicine 
procedures and no coherent, standardized sys‑
tem for providing remote medical services, with 
the only exceptions being teleconsultations and 
hybrid telerehabilitation. There is an unques‑
tionable need to establish clear rules for tele‑
medicine use in Poland, which would ensure 
their high ‑quality and adequate funding.
The variety of uses for modern telemedicine 
technologies presented in this paper shows 
the validity of the phrase “disease telemanage‑
ment,” which refers to a commonly accessible, 
well ‑coordinated, comprehensive healthcare 
system, that integrates all levels of healthcare.100
This paper includes both the commonly avail‑
able solutions and those that are expected to de‑
velop rapidly in the near future. The indications 
for the use of telemedicine are expected to pro‑
gressively expand in scope. However, we would 
like to emphasize that the development of this 
aspect of cardiology requires specialist supervi‑
sion and documenting clinical usefulness of tele‑
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